New study published
(Thomson Reuters ONE) -
Press Release 10th of November 2010
New study published:
Lactobacillus reuteri Prodentis effective in the treatment of periodontitis
The study shows that L. reuteri Prodentis acts synergistically with standard
treatment (scaling and root plaining, SRP) to significantly reduce probing
pocket depth (PPD) and clinical attachment level (CAL) which are the two most
important parameters to assess the severity of periodontitis. Furthermore L.
reuteri Prodentis reveals - as the first probiotic ever - significant reductions
of three different pathogens in patients with chronic periodontitis. The study
also confirms the anti-inflammatory effects of L. reuteri Prodentis on gum
inflammation (gingivitis).
Chronic periodontitis occurs in up to 40 % of the adult population. The standard
treatment aims at removing plaque in the dental pockets to reduce the
periodontal pathogens and thereby prevent disease progression.
Thirty chronic periodontitis patients were included in the double blind,
randomized, placebo-controlled clinical trial that lasted for 42 days. On day 0
the teeth in one half of the mouth were treated with SRP whereas the teeth in
the other half were left untreated. From day 21 to day 42 the patients were
supplemented with either L. reuteri Prodentis lozenges (1X10(8) CFU DSM 17938
and 1x10(8) CFU ATCC PTA 5289) or placebo lozenges twice daily.
The result showed that a combination of L. reuteri Prodentis and SRP was
significantly better than all other modalities in reducing gingivitis and
plaque. Moreover, L. reuteri Prodentis, either alone or following SRP,
significantly reduced the pathogens Aggregibacter actinomycetemcomitans,
Porphyromonas gingivalis and Prevotella intermedia by up to 90 % as compared to
the treatments that did not include L. reuteri Prodentis. The combination of L.
reuteri Prodentis and SRP was also significantly better than SRP alone in
reducing both PPD (p<0.001) and CAL (p<0.001), see attachment.
- This short-term study proves that L. reuteri Prodentis by itself has a
powerful effect on the pathogens of periodontitis and that the combination of L.
reuteri Prodentis and SRP synergistically improves both PPD and CAL, says
Professor Vandana at the College of Dental Science in Davangere, India.
- The results strengthen L. reuteri Prodentis position as a proven treatment
option for patients with periodontal disease, says Peter Rothschild, President,
BioGaia AB.
The results of the study were published online on the 2nd of November 2010 in
the Journal of Oral Microbiology, doi: 10.3402/jom.v2i0.5344. The study can be
accessed at:
http://www.journaloforalmicrobiology.net/index.php/jom/article/view/5344
Latest press releases from BioGaia:
2010-10-27 Interim report 1 January-30 September
2010
2010-09-30 Number of shares in BioGaia
2010-09-23 BioGaia and SCA sign collaboration
agreement
For additional information contact:
Peter Rothschild, President, telephone: +46 8 -555 293 00
K. L. Vandana, Professor, College of Dental Science, Davangere, India, e-mail:
vanrajs(at)gmail.com
BioGaia is a biotechnology company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic,
health-enhancing effects. The class B share of the Parent Company BioGaia AB is
quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com
[HUG#1460906]
graph:
http://hugin.info/86913/R/1460906/399981.pdf
Lactobacillus reuteri Prodentis effective in the treatment of periodontitis:
http://hugin.info/86913/R/1460906/399980.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioGaia AB via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 10.11.2010 - 09:51 Uhr
Sprache: Deutsch
News-ID 48617
Anzahl Zeichen: 4786
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New study published"
steht unter der journalistisch-redaktionellen Verantwortung von
BioGaia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
